Schwalbe Ec, Schwalbe E

List of Publications by Citations

28 papers	877 citations	13 h-index	29 g-index
32 ext. papers	1,248 ext. citations	7.4 avg, IF	3.68 L-index

#	Paper	IF	Citations
28	Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. *Lancet Oncology, The*, **2017**, 18, 958-971	21.7	248
27	DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. *Acta Neuropathologica*, **2013**, 125, 359-71	14.3	95
26	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. *Acta Neuropathologica*, **2019**, 138, 309-326	14.3	90
25	MBCL-31. A WHOLE CHROMOSOME ABERRATION PHENOTYPE IN NON-WNT/NON-SHH TUMORS PREDICTS OUTCOME WITHIN STANDARD-RISK MEDULLOBLASTOMAS FROM THE HIT-SIOP-PNET4 CLINICAL TRIAL. *Neuro-Oncology*, **2018**, 20, i123-i123	1	78
24	ATRT-20. INTRA- AND EXTRA-CRANIAL MALIGNANT RHABDOID TUMOURS SHARE COMMON LOCATION-INDEPENDENT CLINICAL AND MOLECULAR DISEASE CHARACTERISTICS. *Neuro-Oncology*, **2018**, 20, i31-i32	1	78
23	Next-generation systematics: An innovative approach to resolve the structure of complex prokaryotic taxa. *Scientific Reports*, **2016**, 6, 38392	4.9	72
22	Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. *Lancet Oncology, The*, **2018**, 19, 1602-1616	21.7	33
21	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. *Nature Communications*, **2020**, 11, 4324	17.4	32
20	Reducing Viability Bias in Analysis of Gut Microbiota in Preterm Infants at Risk of NEC and Sepsis. *Frontiers in Cellular and Infection Microbiology*, **2017**, 7, 237	5.9	29
19	Genomic analysis of endemic clones of toxigenic and non-toxigenic Corynebacterium diphtheriae in Belarus during and after the major epidemic in 1990s. *BMC Genomics*, **2017**, 18, 873	4.5	19
18	Analysis of Listeria using exogenous volatile organic compound metabolites and their detection by static headspace-multi-capillary column-gas chromatography-ion mobility spectrometry (SHS-MCC-GC-IMS). *Analytical and Bioanalytical Chemistry*, **2017**, 409, 4247-4256	4.4	18
17	Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. *Epigenetics*, **2015**, 10, 717-26	5.7	17
16	SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain. *Leukemia*, **2019**, 33, 1881-1894	10.7	14
15	A chromatographic approach to distinguish Gram-positive from Gram-negative bacteria using exogenous volatile organic compound metabolites. *Journal of Chromatography A*, **2017**, 1501, 79-88	4.5	13
14	Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. *The Lancet Child and Adolescent Health*, **2020**, 4, 865-874	14.5	12
13	The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants . *Pediatric Infectious Disease Journal*, **2017**, 36, e328-e333	3.4	7
12	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. *American Journal of Neuroradiology*, **2019**, 40, 1811-1817	4.4	5

List of Publications

11	Human Bone Proteomes before and after Decomposition: Investigating the Effects of Biological Variation and Taphonomic Alteration on Bone Protein Profiles and the Implications for Forensic Proteomics. *Journal of Proteome Research*, **2021**, 20, 2533-2546	5.6	4
10	Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics. *Neuropathology and Applied Neurobiology*, **2021**, 47, 736-747	5.2	3
9	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. *Neuro-Oncology*, **2021**,	1	3
8	The Effects of Inter-Individual Biological Differences and Taphonomic Alteration on Human Bone Protein Profiles: Implications for the Development of PMI/AAD Estimation Methods		2
7	Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma. *Pharmacology & Therapeutics*, **2021**, 228, 107828	13.9	2
6	Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting - the Blantyre experience. *British Journal of Haematology*, **2020**, 191, e87-e90	4.5	1
5	Response: Commentary: Reducing Viability Bias in Analysis of Gut Microbiota in Preterm Infants at Risk of NEC and Sepsis. *Frontiers in Cellular and Infection Microbiology*, **2018**, 8, 374	5.9	1
4	Integration of genome-level data to allow identification of subtype-specific vulnerability genes as novel therapeutic targets. *Oncogene*, **2021**, 40, 5213-5223	9.2	1
3	MEDB-71. Molecular characterisation of group 4 medulloblastoma improves risk-stratification and its biological understanding. *Neuro-Oncology*, **2022**, 24, i123-i123	1	
2	MEDB-43. Development of a bioinformatics pipeline for identification of differential DNA methylation events associated with medulloblastoma relapse. *Neuro-Oncology*, **2022**, 24, i115-i115	1	
1	MEDB-65. Molecular subclassification of a national cohort of pediatric medulloblastoma based on methylation profile. *Neuro-Oncology*, **2022**, 24, i121-i121	1	